Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen

Maximum deal value of EUR 695 million plus royalties and development cost reimbursement

15-Jul-2011 - Micromet, Inc. announced that it has entered into a collaboration agreement with Amgen Inc. for the research of BiTE antibodies against three undisclosed solid tumor targets. Amgen will have the right to pursue development and commercialization of BiTE antibodies against up to two of these ...

Affitech signs license agreement for single-chain antibody technology with Micromet

30-Mar-2007 - Affitech AS announced that it has signed an agreement with Micromet AG for a non-exclusive worldwide sub-licensable research license to the joint patent estate of Micromet and Enzon Pharmaceuticals, Inc. in the field of single-chain antibodies (SCA). Under the terms of the agreement, Affitech ...

Micromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and Commercialize Antibody D93

Start of Phase 1 Clinical Trial Planned for the Second Half of This Year

20-Mar-2007 - Micromet, Inc. and TRACON Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development of products for cancer treatment, announced an agreement granting TRACON exclusive worldwide rights to develop and commercialize Micromet's D93 antibody with a novel mode of ...